We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
JAYPIRCA Eli Lilly Australia Pty Ltd
Product name
JAYPIRCA
Sponsor
Accepted date
Mar-2025
Active ingredients
pirtobrutinib
Proposed indication
Jaypirca (pirtobrutinib) is used to treat adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor (a type of anti-cancer medicine).
Application type
A (new medicine)
Publication date
Mar-2025